Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KCNJ6 | P48051 | 7/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854538 | 0.86 | KDM4E (0.53) | JAK2JAK1GAAKCNJ6KCNJ3 | |
| SCHEMBL30640604 | 0.85 | JAK2 (0.47) | JAK2JAK1POLBCCNA2CDK2 | |
| SCHEMBL26857654 | 0.84 | JAK2 (0.45) | JAK2JAK1GAAKCNJ6KCNJ3 | |
| SCHEMBL2854953 | 0.83 | SMN1; SMN2 (0.50) | JAK2JAK1GAAPIK3CDKDM1A | |
| SCHEMBL4714665 | 0.82 | KCNJ6 (0.48) | JAK2JAK1GAAKCNJ6KCNJ3 | |
| SCHEMBL31703858 | 0.81 | JAK2 (0.47) | JAK2JAK1PIK3CDPDE10A | |
| SCHEMBL5225046 | 0.80 | KCNJ6 (0.48) | JAK2JAK1GAAKCNJ6KCNJ3 | |
| SCHEMBL14107734 | 0.79 | PIK3CD (0.53) | JAK2JAK1KCNT1PIK3CDKDM1A | |
| SCHEMBL6991912 | 0.79 | JAK2 (0.46) | JAK2JAK1KCNJ6KCNJ3KCNT1 | |
| SCHEMBL2858001 | 0.78 | GRM5 (0.70) | POLBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | JAK2 1925/4885JAK1 3303/4885GAA 4722/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | JAK2 1925/4885JAK1 3303/4885GAA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.